All Online

1 - 4 of 4 results


Active filters


In the U.S., about 15.1 million people have an alcohol use disorder and about 4.8 million misuse opioids. This session focuses on the pharmacotherapy of alcohol and opioid use disorders. The faculty will describe and contrast naltrexone and acamprosate treatments for alcohol use disorder and discuss the use of buprenorphine/naloxone to treat opioid use disorder.


The routine use of UDT according to current prescription drug monitoring guidelines allows for a comprehensive assessment of opioid misuse grounded in policy rather than decisions based on individual patient characteristics, decreasing the stigma that can be associated with this type of testing.


This session offers a "state-of-the-art" review of 2018 Addiction Medicine in the context of our current understanding of the addictive process. We will study how neurobiology approaches craving and control, and how these novel concepts inform our treatment options, both pharmacological and psychosocial.


Providers are under increasing pressure to ensure safe and effective prescribing of chronic opiates in light of the opiate epidemic. When a provider needs to taper a dose or wean a patient off chronic opiates, providers may have a lack of knowledge and comfort on how to do so while minimizing symptoms to the patient. This talk will review the signs and symptoms of withdrawal, who is at risk of withdrawal and medications providers can use to minimize withdrawal symptoms. Participants will also walk away with practical rules and guidelines on how to wean patients off chronic opiates or taper to a lower dose. Finally, the talk will review options for transitioning patients to addiction treatment. Participants will get to practice what they learn through several interactive cases.